Neumora Therapeutics Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Valuation Ratios
P/B Ratio5.975.55
Price/Tangible Book5.975.55
Enterprise Value Ratios
Profitability & Returns
Return on Equity (ROE)-0.64%-0.54%-0.33%-0.80%-1.06%
Return on Assets (ROA)-0.41%-0.26%-0.18%-0.16%
Return on Capital Employed (ROCE)-0.92%-0.40%-0.30%-0.20%-0.14%
Leverage & Solvency Ratios
Debt/Equity0.010.010.020.010.01
Liquidity Ratios
Current Ratio10.5119.0516.3717.8520.69
Quick Ratio10.2918.0815.7317.5920.50
Efficiency Ratios
Yield & Distribution Ratios
Earnings Yield-0.14%-0.09%
FCF Yield-0.11%-0.06%
Buyback Yield-1.45%-1.39%-0.24%-0.68%